Fibryga

FIBRYGA contains human fibrinogen, a protein vital for blood clotting, and replaces missing fibrinogen to correct clotting deficiencies.

Form
injektio-/infuusiokuiva-aine ja liuotin, liuosta varten
Strength
1 g
Active Ingredient
Human fibrinogen
Manufacturer
Octapharma AB

How to Use

Dosage

The dose is determined by your doctor based on your weight, the severity of your condition, the bleeding site or procedure, and your health. Typically, an initial dose of 1-2g is given, followed by additional infusions as needed for acquired fibrinogen deficiency.

Method

This medicine is given slowly into a vein (intravenously) by a healthcare professional as an injection or infusion after being prepared with the supplied solvent.

Important

Your doctor will monitor your fibrinogen levels with blood tests to avoid overdose. In severe bleeding situations, larger doses (4-8 g) might be needed. The dose is adjusted based on your condition and blood test results.

Possible Side Effects

RARE
  • Allergic or anaphylactic skin reactions, such as rash or skin redness.
  • Cardiovascular effects: inflammation of veins (phlebitis) and formation of blood clots.
  • Increase in body temperature (fever).

Important Warnings

  • Do not use FIBRYGA if you are allergic to human fibrinogen or any other ingredient in this medicine, or if you have previously had allergic reactions to FIBRYGA.
  • There is a risk of blood clots, especially with high or repeated doses, or if you have a history of heart attack, liver disease, recent or upcoming surgery, are a newborn, or are otherwise at risk for blood clot problems. Your doctor will monitor this risk.
  • Watch for early signs of allergic reactions, such as hives, rash, chest tightness, wheezing, or low blood pressure. If any of these occur, stop the infusion immediately and contact a doctor.
  • Despite precautions, there is a small risk of transmitting infections, including new or unknown viruses, when using medicines made from human blood or plasma.
  • Parvovirus B19 infection can be serious for pregnant women (due to risk to the unborn child), people with weakened immune systems, or those with certain types of anemia.
Show 1 more warnings
  • Always record the product name and batch number of FIBRYGA each time you receive a dose to maintain a record of the batches used.